Head-to-head evidence
fluticasone furoate/umeclidinium/vilanterol vs Glycopyrrolate/formoterol fumarate
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanisms: Muscarinic acetylcholine receptor (M3) · Beta-2 adrenergic receptor · full Chronic Obstructive Pulmonary Disease pipeline
fluticasone furoate/umeclidinium/vilanterol · Trelegy Ellipta
Marketed by GlaxoSmithKline
NCT02164513 · Phase 3 · completed
This was a large randomized, double-blind, active-controlled trial in 10,355 COPD patients at 971 sites in 37 countries; the primary endpoint, annual on-treatment moderate/severe exacerbation rate, is a hard clinical outcome, and triple therapy significantly reduced exacerbations versus both dual-therapy comparators (rate ratio 0.75 vs UMEC/VI and 0.85 vs FF/VI, both p<0.001).
Next expected readout: September 2027 · NCT07192016 (registry estimate)
Glycopyrrolate/formoterol fumarate · Bevespi Aerosphere
Marketed by AstraZeneca
NCT03324607 · Phase 2/3 · completed
The study used a single treatment group without randomization, blinding, or a placebo or active comparator, and only 17 participants contributed to the primary imaging analysis. Its primary endpoints were surrogate MRI measures rather than established clinical outcomes, and the findings were mixed across those measures, so they provide limited evidence about Bevespi’s clinical effectiveness.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: fluticasone furoate/umeclidinium/vilanterol's landscape · Glycopyrrolate/formoterol fumarate's landscape